BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soriano V, Tefferi A. Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges. Cancer 2018;124:1647-9. [PMID: 29486060 DOI: 10.1002/cncr.31291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Zheng J, Hao J, Wang RR, Liu X, Gu P, Yu H, Yu Y, Wu C, Ou B, Peng Z. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med 2022. [PMID: 35118819 DOI: 10.1002/cam4.4551] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
3 Li WH, Li D. Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer. Medicine (Baltimore) 2019;98:e15255. [PMID: 31008963 DOI: 10.1097/MD.0000000000015255] [Reference Citation Analysis]
4 Ramos-Rincon JM, Menchi-Elanzi M, Pinargote-Celorio H, Mayoral A, González-Alcaide G, de Mendoza C, Barreiro P, Gómez-Gallego F, Corral O, Soriano V. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. AIDS 2022;36:249-56. [PMID: 34762389 DOI: 10.1097/QAD.0000000000003105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holten J, Xie F, Druyts E. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. [PMID: 31922124 DOI: 10.1016/j.eclinm.2019.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
6 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Soriano V, Aguilera A, Gonzalez R, Gomez-Gallego F, Barea L, Treviño M, Corral O. Occult hepatitis B and HIV infection. Eur J Gastroenterol Hepatol 2019;31:1403-7. [PMID: 30969194 DOI: 10.1097/MEG.0000000000001417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A, Routy J, Enel P, Philibert P, Lafeuillade A. Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16–18 May 2018, Marseille, France: from HIV and comorbidities to global health. Journal of Virus Eradication 2018;4:196-207. [DOI: 10.1016/s2055-6640(20)30271-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Hill LA, Delmonte RJ, Andrews B, Richards L, Soto R, Collier S, Kuo A, Cachay E. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol 2018;30:1378-83. [PMID: 29975243 DOI: 10.1097/MEG.0000000000001195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]